Bayer stock

BAYN · Xetra · EUR

€57.04Change from previous close: +0.92%Absolute change: +€0.52

Close · November 16, 2026

Price history

+104.12% over the period

1 year: from €27.94 (November 17, 2025) to €57.04 (November 16, 2026), +104.12%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€57.04
October 30, 2026€50.58
September 30, 2026€47.95
August 31, 2026€49.04
July 31, 2026€48.05
June 30, 2026€48.41
May 29, 2026€36.53
April 30, 2026€38.05
March 31, 2026€39.38
February 27, 2026€42.01
January 30, 2026€44.56
December 30, 2025€37.01
November 28, 2025€30.49
November 17, 2025€27.94

At a glance

  • The company

    Life science company producing pharmaceuticals, consumer health products, and crop protection solutions across multiple therapeutic areas and global markets

  • Latest results

    Quarter to September 30, 2026 · EPS €0.31 (estimate €0.44)

TickerLandia's take on Bayer

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€26.64
52-wk high€57.84

−1.38% from the 52-week high

Analysts · 18 analysts

Average target€60.11+5.38% vs. price

Buy 13 · Hold 4 · Sell 1 · Buy

TickerLandia Fingerprint: Bayer

Compared with similar companies: very low profitability, very strong momentum, and very low growth.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Bayer is cheaper than similar companies

Bayer's Forward P/E: 11.7, −10% against the median of a group of 10 similar companies (13.1).

Compared with 10 similar companies

Bayer's metrics compared with similar companies
MetricBayerPosition in the groupBand
Forward P/E11.7Middle
Operating margin16.5%Low
ROE-4.6%Low
Debt/equity1.34High
Price/book1.90Low

Grey band: the middle half of the group; tick: the median; dot: Bayer. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€10.05B

Latest quarter · Q3 2026

Net income

-€672M

Latest quarter · Q3 2026

Quarterly net margin

-6.7%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
€55.53B
EPS
-€1.47
Volume
1.89M
Daily trading
€146.18M
Dividend yield
0.19%
Last ex-dividend on April 27, 2026

How Bayer is changing

All results
  • Revenue grew 1.9% a year on average over the last 5 years

  • Operating margin fell from 18.0% to 11.2%

  • Revenue has fallen for 3 fiscal years in a row

Returns

Bayer returns with dividends

€1,000 invested in Bayer 5 years ago, on November 16, 2021, would be worth €1,240 today with dividends reinvested: +23.95% in total, +4.39% per year. On price alone it would be €1,138 (+13.81%).

PeriodBayerDAX€1,000 becomes
1 month+28.30%+5.90%€1,283
6 months+51.26%+11.69%€1,513
Year to date+54.12%+9.23%€1,541
1 year+104.70%+13.39%€2,047
3 years+42.13%+69.45%€1,421
5 years+23.95%+64.64%€1,240
10 years−16.77%+150.85%€832

Over the last 6 months it has done better than 75% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment

The chart in detail

Bayer: technical analysis

Bayer is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 60.4% below its all-time closing high (€143.87, April 10, 2015).

Trend
Upward
RSI (14 sessions)
76
Above 70: a strong rise in a short time
vs 200-session average
+29.18%

Active signals

  • RSI above 70: the stock has risen a lot in a short time.

    since November 3, 2026

Support and resistance

Price areas where Bayer has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€57.04
  3. Support€50.14−12.10%5 touches, last on September 14, 2026
  4. Support€47.20−17.26%3 touches, last on September 18, 2026
  5. Support€45.66−19.95%2 touches, last on October 15, 2026

Volatility and risk

Over the last year it has moved roughly in line with the DAX.

Beta (1 year) vs DAX
0.84
Volatility (60 sessions, annualised)
31.7%
Largest fall in the last year
−30.85%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Bayer: seasonality

Average monthly price change over 30 years

+0.8%Jan−0.8%Feb+0.1%Mar+3.2%Apr−0.4%May+1.8%Jun+0.7%Jul−3.1%Aug−1.9%Sep+0.2%Oct+3.1%Nov+2.4%Dec

Over the last 30 years, the strongest month for Bayer has been April: +3.24% on average, positive in 17 years out of 30. The weakest has been August: −3.08% on average, positive in 12 years out of 30. November, the current month, has been positive in 19 years out of 29 (+3.15% on average).

Show chart data
MonthAverageMedianPositive years
January+0.77%+0.71%17 of 30
February−0.81%−1.07%13 of 30
March+0.14%+0.52%15 of 30
April+3.24%+1.53%17 of 30
May−0.41%+0.23%15 of 30
June+1.85%+0.19%15 of 30
July+0.68%+1.51%19 of 30
August−3.08%−1.89%12 of 30
September−1.85%−3.78%12 of 30
October+0.21%+2.69%19 of 30
November+3.15%+4.35%19 of 29
December+2.42%+3.02%18 of 29

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Bayer and its competitors

Known for prescription medicines in cardiology and women's health, contrast agents for diagnostic imaging, and over-the-counter products for self-medication, Bayer also sells crop protection products, seeds and digital farming solutions. Its Pharmaceuticals, Consumer Health and Crop Science segments reach customers through wholesalers, pharmacies, supermarkets, online and other retailers, and hospitals, while farmers are supplied directly. The company operates in Europe, Germany, Switzerland, North America, the United States, Asia Pacific, China, Latin America, Brazil, Africa and the Middle East.

Headquarters
Leverkusen, Germany
Employees
87,775
Founded
1863
Chief executive
William Anderson
Bayer and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
BayerBAYN$61.37B16.5%—+51.26%
GSKGSK$101.36B30.5%17.9+3.57%
SanofiSAN$116.24B22.3%25.3+18.71%
Novo NordiskNOVO.B$181.48B50.8%10.9−3.84%
OrionORNAV$15.93B38.1%22.0+52.14%
AstraZenecaAZN$286.82B25.8%26.5+2.92%

Same industry or related industries, similar size. Compare Bayer with its competitors · Full profile